Benjamin Comer
Benjamin Comer bio
Ben Comer is senior editor at Pharmaceutical Executive. Prior to joining PE, he worked as a reporter for several years at Haymarket Media's Medical Marketing & Media magazine, covering professional and consumer pharmaceutical marketing strategy and tactics, traditional and digital media, and U.S. regulatory policy. Ben is a licensed but no-longer-practicing pharmaceutical technician, and a voracious reader. In 2005, he received an undergraduate degree in journalism and media studies from the College of Charleston, South Carolina, and taught an English language class in Zhuji, China, in 2004, though he unfortunately speaks very little Mandarin. Ben’s reportage at Medical Marketing & Media (MM&M) has been published variously in aggregate online, and his work has also appeared in PR Week and Direct Marketing News, sister titles to MM&M, and most recently the Green Hills News, a local newspaper in Nashville, Tennessee. Aside from journalistic endeavors, Ben has worked as a boom operator on independent films in the New York City area, a bike courier (very briefly), a screenwriter (unpaid), and an unpublished fiction writer.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
